doi: 10.1158/1535-7163.MCT-14-0144 236 LylesRDZMartinezMJShermanBSchurerSBurnsteinKL
Wegovy (semaglutide 2.4 mg) was FDA-approved for chronic weight management in June 2021 and received a supplemental approval for cardiovascular risk reduction in March 2024
This suggests that the antidepressant effects of semaglutide, via GLP-1 receptor activation, may be closely linked to its neuroprotective and anti-inflammatory properties
(PubMed) Dalmeijer GW, Olthof MR, Verhoef P, Bots ML, van der Schouw YT
In June, trials were released on new formulations that may be even more effective
How Tirzepatide Is Different Tirzepatide is often described as a dual agonist because it targets two hormone systems: GLP1 and GIP (glucosedependent insulinotropic polypeptide)